Pfizer Inc. (NYSE:PFE) is trading up 21.63% versus 12-month low of 27.49 and stands -8.92% lower from its 1-year peak of $36.72. The consensus price target (PT) of $37.65 means that the market expects Company shares to increase by 12.5% in the short run. The sell-side target prices range from $30 to $53. In the last month the stock has moved in price 8.08%, with a one year change of 11.70%. The last trading session volume compares with the 26.17M average and market worth floats around 203.71B.
Pfizer Inc. (NYSE:PFE) fell -0.09% to reach at the trading price of $33.44 as it is set to release its next quarterly earnings report on January 31, 2017. Pfizer Inc. stock trades in the range of $33.32 to $33.66 before the earnings release. Let’s take a closer look at the current earnings forecast, particularly the things traders should pay close attention to. Earnings per share for the recently concluded quarter is expected to come in at $0.5 a share with $13.67B in revenue.
Pfizer Inc. (PFE) Future Earnings & History
After upcoming fiscal quarter results, all eyes will be on the prospects for the next reporting quarter. Analysts, on average, forecast Pfizer Inc. to earn $0.67 per share (EPS) on revenue of $13.51B. The EPS consensus range is $0.64-$0.69 on revenue between $13.65B and $13.28B.
While if we look at the Earnings Track Record, Pfizer Inc. (PFE) managed to surpass quarterly earnings per share estimates in 11 of the trailing twelve fiscal quarters, and has a positive trend with an average surprise of 91%. Last time the company reported, Pfizer Inc. (PFE) generated $0.61 in earnings per share, missing the consensus estimate of $0.62. Revenues hit $13.05B in the September 2017 quarter, which was above the consensus $13.04B projection. On the other hand, in the June 2017 quarter the company recorded a net $13.15B revenue with earnings per share of $0.64. Wall Street had anticipated $13.01B and $0.62, respectively. For comparison, there was a revenue of $13.01B and EPS of $0.67 in the March 2016 period.
Pfizer Inc. (NYSE:PFE) Analyst Insights
The buoyancy in the outlook of Pfizer Inc. (PFE) is getting weaker by the somewhat negative sentiment (2.50 on a 5-point scale) that sell-side analysts have provided concerning it. Brokerage firms on the average advocate the company shares as Overweight. Argus has been covering shares of PFE, so it is most recent view is worth a look. In a research note issued on Nov 02, 2016, analysts at downgraded the stock to Hold from Buy. Another noteworthy analyst activity was recorded on Oct 13, 2016. Downgraded the stock to Hold from Buy.